Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?

Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?

Tissue fibrosis causes organ failure and death in patients with systemic sclerosis (SSc), but clearly effective anti-fibrotic therapies are not available. The tyrosine kinase inhibitor (TKI) imatinib, which blocks the pro-fibrotic c-Abl kinase and PDGF receptor, is currently evaluated in clinical...

Full description

Bibliographic Details
Main Authors: C Beyer, O Distler, JH Distler
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2010-08-01
Series:Swiss Medical Weekly
Subjects:
fibrosis
systemic sclerosis
tyrosine kinase inhibitors
Online Access:https://www.smw.ch/index.php/smw/article/view/1177

Similar Items

Similar Items